Table 4 |
|||||
| Variance in preoperative clinicopathological parameters between patients with and without peruneural invasion (PNI) | |||||
|
PNI present (n = 63) |
PNI absent (n = 61) |
Univariate | Multivariate | ||
| P value | P value | Adjusted odds ratio (95% CI) | |||
| Mean age [years] | 63.7 ± 5.0 | 64.0 ± 5.0 | 0.894 | ||
| PSA [ng/ml] | 9.5 ± 5.9 | 8.5 ± 8.5 | 0.104 | ||
| Gleason score at biopsy | 7.4 ± 1.1 | 6.7 ± 0.9 | <0.001 | 0.001 | 1.983 (1.342-2.929) |
| cT stage (n) | 0.615 | ||||
| T1c | 49 (77.8%) | 50 (82.0%) | |||
| T2 | 9 (14.3%) | 9 (14.8%) | |||
| T3a | 5 (7.9%) | 2 (3.3%) | |||
| %positive cores | 23.5 ± 18.7 | 19.8 ±14.8 | 0.513 | ||
| TZ biopsy positive (n) | 24 (38.1%) | 18 (29.5%) | 0.312 | ||
| Number of apex-positive (2–4/0–1) (n) | 14/49 | 15/46 | 0.755 | ||
| Number of middle-positive (2–4/0–1) (n) | 21/42 | 13/48 | 0.134 | ||
| Number of base-positive (2–4/0–1) (n) | 17/46 | 10/51 | 0.153 | ||
PSA, prostate-specific antigen; TZ, transition zone; apex, prostatic apex biopsy; middle, prostatic middle biopsy; base, prostatic base biopsy.
Ishizaki et al. Diagnostic Pathology 2012 7:68 doi:10.1186/1746-1596-7-68
